Will JP Morgan’s AI Advisor Be a Winner?
JPMorgan Chase is rolling out “JPM WealthAI for high-net-worth clients.…
Sell
4
PIII Quote, Financials, Valuation and Earnings
Last price:
$0.15
Seasonality move
:
21.9%
Day range:
$0.15 - $0.17
52-week range:
$0.14 - $0.81
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.01x
P/B ratio:
0.33x
Volume:
398.7K
Avg. volume:
675.8K
1-year change:
-74.54%
Market cap:
$24.7M
Revenue:
$1.5B
EPS (TTM):
-$0.86
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PIII
P3 Health Partners
|
$349.8M | -$0.09 | -7.74% | -- | $0.63 |
|
AMS
American Shared Hospital Services
|
$8.4M | $0.04 | 18.76% | -92.73% | $4.84 |
|
ASTH
Astrana Health
|
$654.2M | $0.45 | 34.54% | 13.44% | $50.4546 |
|
CCEL
Cryo-Cell International
|
$8M | $0.03 | -0.02% | -62.5% | $8.50 |
|
OMCL
Omnicell
|
$279.1M | $0.42 | 5.71% | 249.27% | $51.00 |
|
PINC
Premier
|
$255.5M | $0.37 | -29.09% | -33.9% | $19.79 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PIII
P3 Health Partners
|
$0.15 | $0.63 | $24.7M | -- | $0.00 | 0% | 0.01x |
|
AMS
American Shared Hospital Services
|
$2.71 | $4.84 | $17.5M | 7.97x | $0.00 | 0% | 0.64x |
|
ASTH
Astrana Health
|
$33.1000 | $50.4546 | $1.5B | 37.19x | $0.00 | 0% | 0.78x |
|
CCEL
Cryo-Cell International
|
$5.43 | $8.50 | $43.9M | 114.60x | $0.25 | 9.21% | 1.39x |
|
OMCL
Omnicell
|
$31.19 | $51.00 | $1.5B | 115.52x | $0.00 | 0% | 1.30x |
|
PINC
Premier
|
$19.21 | $19.79 | $1.8B | 14.37x | $0.21 | 4.37% | 1.68x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PIII
P3 Health Partners
|
52.54% | 0.317 | 64.79% | 0.47x |
|
AMS
American Shared Hospital Services
|
45.9% | 0.382 | 90.05% | 1.35x |
|
ASTH
Astrana Health
|
37.88% | 0.562 | 33.16% | 1.68x |
|
CCEL
Cryo-Cell International
|
917.71% | 1.052 | 21.46% | 0.52x |
|
OMCL
Omnicell
|
21.51% | 1.628 | 16.5% | 1.07x |
|
PINC
Premier
|
8.08% | 0.697 | 7.77% | 0.73x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PIII
P3 Health Partners
|
-- | -$107M | -20.12% | -26.35% | -27.84% | -$22.6M |
|
AMS
American Shared Hospital Services
|
$1.4M | -$553K | 8.36% | 13.75% | -3.47% | -$407K |
|
ASTH
Astrana Health
|
$50.5M | $720K | 4.97% | 9.13% | 0.93% | -$13.5M |
|
CCEL
Cryo-Cell International
|
$5.9M | $1.4M | -330.65% | -- | 23.72% | $2.1M |
|
OMCL
Omnicell
|
$141.8M | $12.4M | 0.72% | 1.04% | 4.04% | $42.7M |
|
PINC
Premier
|
$171.2M | -$92.8M | -0.23% | -0.24% | -38.63% | $89.5M |
P3 Health Partners vs. Competitors
-
Which has Higher Returns PIII or AMS?
American Shared Hospital Services has a net margin of -12.84% compared to P3 Health Partners's net margin of -2.96%. P3 Health Partners's return on equity of -26.35% beat American Shared Hospital Services's return on equity of 13.75%.
Company Gross Margin Earnings Per Share Invested Capital PIIIP3 Health Partners-- -$0.31 $397.3M AMSAmerican Shared Hospital Services19.57% -$0.03 $54.2M -
What do Analysts Say About PIII or AMS?
P3 Health Partners has a consensus price target of $0.63, signalling upside risk potential of 312.27%. On the other hand American Shared Hospital Services has an analysts' consensus of $4.84 which suggests that it could grow by 78.6%. Given that P3 Health Partners has higher upside potential than American Shared Hospital Services, analysts believe P3 Health Partners is more attractive than American Shared Hospital Services.
Company Buy Ratings Hold Ratings Sell Ratings PIIIP3 Health Partners2 2 0 AMSAmerican Shared Hospital Services0 0 0 -
Is PIII or AMS More Risky?
P3 Health Partners has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison American Shared Hospital Services has a beta of 0.424, suggesting its less volatile than the S&P 500 by 57.593%.
-
Which is a Better Dividend Stock PIII or AMS?
P3 Health Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. American Shared Hospital Services offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. P3 Health Partners pays -- of its earnings as a dividend. American Shared Hospital Services pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PIII or AMS?
P3 Health Partners quarterly revenues are $362.1M, which are larger than American Shared Hospital Services quarterly revenues of $7M. P3 Health Partners's net income of -$46.5M is lower than American Shared Hospital Services's net income of -$207K. Notably, P3 Health Partners's price-to-earnings ratio is -- while American Shared Hospital Services's PE ratio is 7.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners is 0.01x versus 0.64x for American Shared Hospital Services. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PIIIP3 Health Partners0.01x -- $362.1M -$46.5M AMSAmerican Shared Hospital Services0.64x 7.97x $7M -$207K
-
Which has Higher Returns PIII or ASTH?
Astrana Health has a net margin of -12.84% compared to P3 Health Partners's net margin of -1.05%. P3 Health Partners's return on equity of -26.35% beat Astrana Health's return on equity of 9.13%.
Company Gross Margin Earnings Per Share Invested Capital PIIIP3 Health Partners-- -$0.31 $397.3M ASTHAstrana Health7.59% -$0.15 $948.8M -
What do Analysts Say About PIII or ASTH?
P3 Health Partners has a consensus price target of $0.63, signalling upside risk potential of 312.27%. On the other hand Astrana Health has an analysts' consensus of $50.4546 which suggests that it could grow by 52.43%. Given that P3 Health Partners has higher upside potential than Astrana Health, analysts believe P3 Health Partners is more attractive than Astrana Health.
Company Buy Ratings Hold Ratings Sell Ratings PIIIP3 Health Partners2 2 0 ASTHAstrana Health10 3 0 -
Is PIII or ASTH More Risky?
P3 Health Partners has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Astrana Health has a beta of 1.044, suggesting its more volatile than the S&P 500 by 4.424%.
-
Which is a Better Dividend Stock PIII or ASTH?
P3 Health Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. P3 Health Partners pays -- of its earnings as a dividend. Astrana Health pays out 9.35% of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PIII or ASTH?
P3 Health Partners quarterly revenues are $362.1M, which are smaller than Astrana Health quarterly revenues of $665.2M. P3 Health Partners's net income of -$46.5M is lower than Astrana Health's net income of -$7M. Notably, P3 Health Partners's price-to-earnings ratio is -- while Astrana Health's PE ratio is 37.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners is 0.01x versus 0.78x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PIIIP3 Health Partners0.01x -- $362.1M -$46.5M ASTHAstrana Health0.78x 37.19x $665.2M -$7M
-
Which has Higher Returns PIII or CCEL?
Cryo-Cell International has a net margin of -12.84% compared to P3 Health Partners's net margin of 13.04%. P3 Health Partners's return on equity of -26.35% beat Cryo-Cell International's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PIIIP3 Health Partners-- -$0.31 $397.3M CCELCryo-Cell International73.65% $0.13 $1.2M -
What do Analysts Say About PIII or CCEL?
P3 Health Partners has a consensus price target of $0.63, signalling upside risk potential of 312.27%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 56.54%. Given that P3 Health Partners has higher upside potential than Cryo-Cell International, analysts believe P3 Health Partners is more attractive than Cryo-Cell International.
Company Buy Ratings Hold Ratings Sell Ratings PIIIP3 Health Partners2 2 0 CCELCryo-Cell International0 0 0 -
Is PIII or CCEL More Risky?
P3 Health Partners has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.607, suggesting its less volatile than the S&P 500 by 39.282%.
-
Which is a Better Dividend Stock PIII or CCEL?
P3 Health Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 9.21% to investors and pays a quarterly dividend of $0.25 per share. P3 Health Partners pays -- of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend.
-
Which has Better Financial Ratios PIII or CCEL?
P3 Health Partners quarterly revenues are $362.1M, which are larger than Cryo-Cell International quarterly revenues of $8.1M. P3 Health Partners's net income of -$46.5M is lower than Cryo-Cell International's net income of $1.1M. Notably, P3 Health Partners's price-to-earnings ratio is -- while Cryo-Cell International's PE ratio is 114.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners is 0.01x versus 1.39x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PIIIP3 Health Partners0.01x -- $362.1M -$46.5M CCELCryo-Cell International1.39x 114.60x $8.1M $1.1M
-
Which has Higher Returns PIII or OMCL?
Omnicell has a net margin of -12.84% compared to P3 Health Partners's net margin of 5.16%. P3 Health Partners's return on equity of -26.35% beat Omnicell's return on equity of 1.04%.
Company Gross Margin Earnings Per Share Invested Capital PIIIP3 Health Partners-- -$0.31 $397.3M OMCLOmnicell46.19% $0.34 $1.6B -
What do Analysts Say About PIII or OMCL?
P3 Health Partners has a consensus price target of $0.63, signalling upside risk potential of 312.27%. On the other hand Omnicell has an analysts' consensus of $51.00 which suggests that it could grow by 63.51%. Given that P3 Health Partners has higher upside potential than Omnicell, analysts believe P3 Health Partners is more attractive than Omnicell.
Company Buy Ratings Hold Ratings Sell Ratings PIIIP3 Health Partners2 2 0 OMCLOmnicell3 5 0 -
Is PIII or OMCL More Risky?
P3 Health Partners has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Omnicell has a beta of 0.785, suggesting its less volatile than the S&P 500 by 21.543%.
-
Which is a Better Dividend Stock PIII or OMCL?
P3 Health Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omnicell offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. P3 Health Partners pays -- of its earnings as a dividend. Omnicell pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PIII or OMCL?
P3 Health Partners quarterly revenues are $362.1M, which are larger than Omnicell quarterly revenues of $306.9M. P3 Health Partners's net income of -$46.5M is lower than Omnicell's net income of $15.8M. Notably, P3 Health Partners's price-to-earnings ratio is -- while Omnicell's PE ratio is 115.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners is 0.01x versus 1.30x for Omnicell. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PIIIP3 Health Partners0.01x -- $362.1M -$46.5M OMCLOmnicell1.30x 115.52x $306.9M $15.8M
-
Which has Higher Returns PIII or PINC?
Premier has a net margin of -12.84% compared to P3 Health Partners's net margin of -39.96%. P3 Health Partners's return on equity of -26.35% beat Premier's return on equity of -0.24%.
Company Gross Margin Earnings Per Share Invested Capital PIIIP3 Health Partners-- -$0.31 $397.3M PINCPremier71.26% -$1.01 $1.9B -
What do Analysts Say About PIII or PINC?
P3 Health Partners has a consensus price target of $0.63, signalling upside risk potential of 312.27%. On the other hand Premier has an analysts' consensus of $19.79 which suggests that it could grow by 3%. Given that P3 Health Partners has higher upside potential than Premier, analysts believe P3 Health Partners is more attractive than Premier.
Company Buy Ratings Hold Ratings Sell Ratings PIIIP3 Health Partners2 2 0 PINCPremier0 7 0 -
Is PIII or PINC More Risky?
P3 Health Partners has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Premier has a beta of 0.516, suggesting its less volatile than the S&P 500 by 48.448%.
-
Which is a Better Dividend Stock PIII or PINC?
P3 Health Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Premier offers a yield of 4.37% to investors and pays a quarterly dividend of $0.21 per share. P3 Health Partners pays -- of its earnings as a dividend. Premier pays out 79.64% of its earnings as a dividend. Premier's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PIII or PINC?
P3 Health Partners quarterly revenues are $362.1M, which are larger than Premier quarterly revenues of $240.3M. P3 Health Partners's net income of -$46.5M is higher than Premier's net income of -$96M. Notably, P3 Health Partners's price-to-earnings ratio is -- while Premier's PE ratio is 14.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners is 0.01x versus 1.68x for Premier. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PIIIP3 Health Partners0.01x -- $362.1M -$46.5M PINCPremier1.68x 14.37x $240.3M -$96M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Revolve Group Stock a Buy, Sell or Hold?
Recently, Revolve Group (NYSE:RVLV) management delivered some fairly positive business…
Is Bloom Energy Stock a Buy, Sell or Hold?
While already interesting as the world moves toward greener energy…
Stock Ideas
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
50
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
52
RGC alert for Apr 12
Regencell Bioscience Holdings [RGC] is up 29.14% over the past day.
Buy
52
SLP alert for Apr 12
Simulations Plus [SLP] is up 26.73% over the past day.
Buy
89
GDXU alert for Apr 12
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 15.9% over the past day.
